|
1
|
Miller AJ and Mihm MC Jr: Melanoma. N Engl
J Med. 355:51–65. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Terando A, Sabel MS and Sondak VK:
Melanoma: Adjuvant therapy and other treatment options. Curr Treat
Options Oncol. 4:187–199. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Penna E, Orso F, Cimino D, Vercellino I,
Grassi E, Quaglino E, Turco E and Taverna D: MiR-214 coordinates
melanoma progression by upregulating ALCAM through TFAP2 and
miR-148b downmodulation. Cancer Res. 73:4098–4111. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baade P and Coory M: Trends in melanoma
mortality in Australia: 1950–2002 and their implications for
melanoma control. Aust N Z J Public Health. 29:383–386. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coory M, Baade P, Aitken J, Smithers M,
McLeod GR and Ring I: Trends for in situ and invasive melanoma in
Queensland, Australia, 1982–2002. Cancer Causes Control. 17:21–27.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sosman JA, Kim KB, Schuchter L, Gonzalez
R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ,
Flaherty KT, et al: Survival in BRAF V600-mutant advanced melanoma
treated with vemurafenib. N Engl J Med. 366:707–714. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wagle N, Emery C, Berger MF, Davis MJ,
Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE,
Hahn WC, et al: Dissecting therapeutic resistance to RAF inhibition
in melanoma by tumor genomic profiling. J Clin Oncol. 29:3085–3096.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lai EC: Micro RNAs are complementary to 3′
UTR sequence motifs that mediate negative post-transcriptional
regulation. Nat Genet. 30:363–364. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh TR, Gupta A and Suravajhala P:
Challenges in the miRNA research. Int J Bioinform Res Appl.
9:576–583. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Phuah NH and Nagoor NH: Regulation of
microRNAs by natural agents: New strategies in cancer therapies.
Biomed Res Int. 2014:8045102014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ling H, Fabbri M and Calin GA: MicroRNAs
and other non-coding RNAs as targets for anticancer drug
development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Blower PE, Verducci JS, Lin S, Zhou J,
Chung JH, Dai Z, Liu CG, Reinhold W, Lorenzi PL, Kaldjian EP, et
al: MicroRNA expression profiles for the NCI-60 cancer cell panel.
Mol Cancer Ther. 6:1483–1491. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sakurai E, Maesawa C, Shibazaki M,
Yasuhira S, Oikawa H, Sato M, Tsunoda K, Ishikawa Y, Watanabe A,
Takahashi K, et al: Downregulation of microRNA-211 is involved in
expression of preferentially expressed antigen of melanoma in
melanoma cells. Int J Oncol. 39:665–672. 2011.PubMed/NCBI
|
|
19
|
Medina PP, Nolde M and Slack FJ: OncomiR
addiction in an in vivo model of microRNA-21-induced pre-B-cell
lymphoma. Nature. 467:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Obad S, dos Santos CO, Petri A, Heidenblad
M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, et al:
Silencing of microRNA families by seed-targeting tiny LNAs. Nat
Genet. 43:371–378. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saito Y, Liang G, Egger G, Friedman JM,
Chuang JC, Coetzee GA and Jones PA: Specific activation of
microRNA-127 with downregulation of the proto-oncogene BCL6 by
chromatin-modifying drugs in human cancer cells. Cancer Cell.
9:435–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu R, Xie H, Luo C, Chen Z, Zhou X, Xia
K, Chen X, Zhou M, Cao P, Cao K and Zhou J: Identification of FLOT2
as a novel target for microRNA-34a in melanoma. J Cancer Res Clin
Oncol. 141:993–1006. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Du B, Wang Z, Zhang X, Feng S, Wang G, He
J and Zhang B: MicroRNA-545 suppresses cell proliferation by
targeting cyclin D1 and CDK4 in lung cancer cells. PLoS One.
9:e880222014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang F, Tang J, Zhuang X, Zhuang Y, Cheng
W, Chen W, Yao H and Zhang S: MiR-196a promotes pancreatic cancer
progression by targeting nuclear factor kappa-B-inhibitor alpha.
PLoS One. 9:e878972014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin
C and Zhang W: MicroRNA-133 inhibits cell proliferation, migration
and invasion in prostate cancer cells by targeting the epidermal
growth factor receptor. Oncol Rep. 27:1967–1975. 2012.PubMed/NCBI
|
|
29
|
Ujifuku K, Mitsutake N, Takakura S,
Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K,
Nagata I and Yamashita S: MiR-195, miR-455-3p and miR-10a (*) are
implicated in acquired temozolomide resistance in glioblastoma
multiforme cells. Cancer Lett. 296:241–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu Z, Shen WJ, Kraemer FB and Azhar S:
MicroRNAs 125a and 455 repress lipoprotein-supported
steroidogenesis by targeting scavenger receptor class B type I in
steroidogenic cells. Mol Cell Biol. 32:5035–5045. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li X, Zhang G, Luo F, Ruan J, Huang D,
Feng D, Xiao D, Zeng Z, Chen X and Wu W: Identification of
aberrantly expressed miRNAs in rectal cancer. Oncol Rep. 28:77–84.
2012.PubMed/NCBI
|
|
32
|
Swingler TE, Wheeler G, Carmont V, Elliott
HR, Barter MJ, Abu-Elmagd M, Donell ST, Boot-Handford RP,
Hajihosseini MK, Münsterberg A, et al: The expression and function
of microRNAs in chondrogenesis and osteoarthritis. Arthritis Rheum.
64:1909–1919. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chai J, Wang S, Han D, Dong W, Xie C and
Guo H: MicroRNA-455 inhibits proliferation and invasion of
colorectal cancer by targeting RAF proto-oncogene
serine/threonine-protein kinase. Tumour Biol. 36:1313–1321. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao X, Dou W, He L, Liang S, Tie J, Liu
C, Li T, Lu Y, Mo P, Shi Y, et al: MicroRNA-7 functions as an
anti-metastatic microRNA in gastric cancer by targeting
insulin-like growth factor-1 receptor. Oncogene. 32:1363–1372.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baserga R, Peruzzi F and Reiss K: The
IGF-1 receptor in cancer biology. Int J Cancer. 107:873–877. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cao Z, Liu LZ, Dixon DA, Zheng JZ,
Chandran B and Jiang BH: Insulin-like growth factor-I induces
cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling
pathways in human ovarian cancer cells. Cell Signal. 19:1542–1553.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Christopoulos PF, Msaouel P and
Koutsilieris M: The role of the insulin-like growth factor-1 system
in breast cancer. Mol Cancer. 14:432015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gryko M, Kiśluk J, Cepowicz D, Zińczuk J,
Kamocki Z, Guzińska-Ustymowicz K, Pryczynicz A, Czyżewska J, Kemona
A and Kędra B: Expression of insulin-like growth factor receptor
type 1 correlate with lymphatic metastases in human gastric cancer.
Pol J Pathol. 65:135–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang YH, Wang ZX, Qiu Y, Xiong J, Chen YX,
Miao DS and De W: Lentivirus-mediated RNAi knockdown of
insulin-like growth factor-1 receptor inhibits growth, reduces
invasion and enhances radiosensitivity in human osteosarcoma cells.
Mol Cell Biochem. 327:257–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang YH, Han XD, Qiu Y, Xiong J, Yu Y,
Wang B, Zhu ZZ, Qian BP, Chen YX, Wang SF, et al: Increased
expression of insulin-like growth factor-1 receptor is correlated
with tumor metastasis and prognosis in patients with osteosarcoma.
J Surg Oncol. 105:235–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Scharf JG and Braulke T: The role of the
IGF axis in hepatocarcinogenesis. Horm Metab Res. 35:685–693. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kanter-Lewensohn L, Dricu A, Wang M, Wejde
J, Kiessling R and Larsson O: Expression of the insulin-like growth
factor-1 receptor and its anti-apoptotic effect in malignant
melanoma: A potential therapeutic target. Melanoma Res. 8:389–397.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Luo M, Shen D, Zhou X, Chen X and Wang W:
MicroRNA-497 is a potential prognostic marker in human cervical
cancer and functions as a tumor suppressor by targeting the
insulin-like growth factor 1 receptor. Surgery. 153:836–847. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xu JW, Wang TX, You L, Zheng LF, Shu H,
Zhang TP and Zhao YP: Insulin-like growth factor 1 receptor
(IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated
with TNM stage of pancreatic cancer. PLoS One. 9:e928472014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lian HW, Zhou Y, Jian ZH and Liu RZ:
MiR-323-5p acts as a tumor suppressor by targeting the insulin-like
growth factor 1 receptor in human glioma cells. Asian Pac J Cancer
Prev. 15:10181–10185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shi ZM, Wang XF, Qian X, Tao T, Wang L,
Chen QD, Wang XR, Cao L, Wang YY, Zhang JX, et al: MiRNA-181b
suppresses IGF-1R and functions as a tumor suppressor gene in
gliomas. RNA. 19:552–560. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang W, Liu K, Liu S, Ji B, Wang Y and
Liu Y: MicroRNA-133a functions as a tumor suppressor by targeting
IGF-1R in hepatocellular carcinoma. Tumour Biol. 36:9779–9788.
2015. View Article : Google Scholar : PubMed/NCBI
|
